Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer: Hormone Sensitive

Join Michael Berry, MD and Lee Schwartzberg, MD from The University of Tennessee Health Science Center as they present their multidisciplinary expertise on a range of cases pertaining to hormone sensitive breast cancer.

Hormone-sensitive breast cancer, defined as estrogen and/or progesterone receptor-positive breast cancer, represents about 80% of breast cancers diagnosed in women under age 50 in the United States. Treatment with an aromatase inhibitor, such as exemestane, compared to treatment with tamoxifen, has previously been demonstrated to benefit postmenopausal breast cancer patients. The results of the SOFT and TEXT randomized phase 3 trials, has expanded endocrine treatment options for premenopausal women with hormone receptor-positive breast cancer to include an aromatase inhibitor in combination with ovarian suppression.

Over time, hormone-sensitive tumors stop responding to endocrine therapies. Therefore, the focus has been on new drug combinations and new drugs that will be effective in advanced hormone-sensitive tumors that have stopped responding to endocrine therapies. One mechanism of resistance to endocrine therapy is activation of the mammalian target of rapamycin (mTOR) signal transduction pathway. A phase III study (BOLERO-2) reported significantly longer progression free survival and overall survival with the mTOR inhibitor, everolimus, plus exemestane versus placebo plus exemestane.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Evaluate the current therapies for hormone-sensitive breast cancer
  • Describe agents currently under clinical investigation for patients with hormone-sensitive breast cancer
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.91 ANCC contact hours
  • 1.00 Participation
Course opens: 
03/02/2016
Course expires: 
03/02/2017
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards (June 2015 - June 2016)

Michael Berry, MD
The University of Tennessee Health Science Center

Lee Schwartzberg, MD
The University of Tennessee Health Science Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have disclosed the following relevant financial relationships:

Lee Schwartzberg, MD
Amgen – Speakers’ Bureau
Bristol Myers Squibb – Scientific Advisor
Caris – Scientific Advisor
Genentech – Speakers’ Bureau
Helsinn – Scientific Advisor
Merck & Co, Inc.  – Scientific Advisor
Tesaro – Scientific Advisor

The faculty listed below have no relevant financial relationships to disclose:

Michael Berry, MD

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Rashmi Kumar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.91 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-013-H01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.91 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing